Kuros Biosciences received FDA 510(k) clearance to market MagnetOs synthetic bone graft putty as an autograft extender in the posterolateral spine. Further, the company has filed for CE Mark approval in the EU.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Per terms of that transaction, the putty clearance triggers a milestone issue of shares to the former owners of Xpand.
Sources: Kuros Biosciences AG; ORTHOWORLD Inc.
Kuros Biosciences received FDA 510(k) clearance to market MagnetOs synthetic bone graft putty as an autograft extender in the posterolateral spine. Further, the company has filed for CE Mark approval in the EU.
MagnetOs was previously cleared in the U.S. in a...
Kuros Biosciences received FDA 510(k) clearance to market MagnetOs synthetic bone graft putty as an autograft extender in the posterolateral spine. Further, the company has filed for CE Mark approval in the EU.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Per terms of that transaction, the putty clearance triggers a milestone issue of shares to the former owners of Xpand.
Sources: Kuros Biosciences AG; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
